Is Prenatal Screening for Rare Diseases Too Costly? Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. 3/17/2010
Enzo Biochem, MultiGEN Diagnostics Sign DNA Sequencing Marketing Agreement Enzo Biochem announced that it has entered into an agreement with MultiGEN Diagnostics Inc, of San Diego for exclusive rights to market MultiGENs unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. 3/16/2010
In Cancer Diagnostics, the Profit Is in Test Services The majority of new cancer tests coming to market are proprietary assays with the test services being provided by certified labs opened by the IVD companies that developed the test. This shift is leading to greater profits for those companies offering test services, notes health care market research publisher Kalorama Information. 3/15/2010
Biosearch Technologies Expands Licensing of Roche Patents Biosearch Technologies Inc announced that the company has expanded its licenses from Roche Molecular Systems. The expanded license grants Biosearch the right to manufacture and sell validated kits to the in-vitro diagnostic (IVD) marketplace as licensed products covered by multiple patents assigned to Roche. 3/11/2010
Experts here are available to answer all your questions!
Sandy Laughlin
